Antemortem diagnostic tests and treatment outcomes using ivermectin in 13 cases of presumptive feline neurocuterebriasis.

Abstract

BACKGROUND: Limited reports exist on the antemortem presumptive diagnosis and treatment of feline neurocuterebriasis. A 3-day treatment protocol reported for 3 cats had no adverse effects. This protocol comprised ivermectin (0.4 mg/kg), diphenhydramine (4 mg/kg), and dexamethasone (0.1 mg/kg) given q24h. OBJECTIVE: To describe the treatment outcomes for cats that received the 3-day ivermectin protocol and antemortem diagnostic methods used before. ANIMALS AND PROCEDURE: Medical records from a single veterinary referral centre were searched to identify cats treated with the 3-day protocol. Variables extracted included signalment, season, history, neurological examination findings, and advanced diagnostic tests, as well as outcomes based on follow-up. RESULTS: Thirteen cats were diagnosed based on advanced imaging. Ten of 13 also underwent cerebrospinal fluid analysis. Other diagnostic factors included season (July through September), signalment (young to middle-aged), lifestyle (outdoor access), history (7/13 cats showed upper respiratory signs preceding neurological deficits), and clinical signs (central neurological deficits). After being treated with the 3-day ivermectin protocol, 10/13 cats improved. Three cats were euthanized after showing worsening clinical signs. CONCLUSION AND CLINICAL RELEVANCE: Outcomes using the 3-day ivermectin protocol appeared favorable. This provided insight about a treatment option for a periodic cause of feline encephalomyelopathy that has potential for deployment in first-opinion practice.